Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in watanabe heritable hyperlipidemic rabbits

General Pharmacology

Volumn 33, Issue 6, 1999, Pages 467-477

  Napoli, Claudio ^a,b   Cicala, Carla ^a   D'Armiento, Francesco P ^a   Roviezzo, Fiorentina ^a   Somma, Pasquale ^a   De Nigris, Filomena ^a   Zuliani, Patrizia ^a   Bucci, Mariarosaria ^a   Aleotti, Lucia ^c   Casini, Alessandro ^c   Franconi, Flavia ^d   Cirino, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c A Menarini Pharmaceutical Industries Ltd   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

Author keywords

Antioxidants; Atherogenesis; LDL oxidation; Platelet; WHHL rabbit; Zofenopril

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PLACEBO; ZOFENOPRIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ENZYME INHIBITION; HYPERLIPIDEMIA; IMMUNOCYTOCHEMISTRY; LIPID OXIDATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE ACTIVATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARTERIOSCLEROSIS; BLOOD PLATELETS; CAPTOPRIL; FEMALE; HYPERLIPOPROTEINEMIA TYPE II; IMMUNOHISTOCHEMISTRY; LIPOPROTEINS, LDL; MALE; RABBITS;

EID: 0033370316     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(99)00043-9     Document Type: Article

References (51)

1. Aberg G., Ferrer P. Effects of captopril on atherosclerosis in cynomologus monkeys. J Cardiovasc Pharmacol. 15:1990;565-572.
2. Ambrosio G., Napoli C., Oriente A., Palumbo G., Chiariello P., Marone G., Chiariello M., Triggiani M. Oxygen radicals inhibit human plasma acethylhydrolase, the enzyme that catabolizes platelet activating factor. J Clin Invest. 93:1994;2408-2416.
3. Ambrosioni, E., Borghi, C., Magnani, B., for the SMILE Study Investigators, 1995. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbility after myocardial infarction. N Engl J Med 333, 80-85.
4. Bombeli T., Schwartz B.R., Harlan J.M. Adhesion of activated platelets to endothelial cells. evidence for a GPIIb-IIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), α,β-integrin, and GPIba J Exp Med. 187:1998;329-339.
5. Braunwald E. Stattuck Lecture-Cardiovascular medicine at the turn of the millennium. triumphs, concerns, and opportunities N Engl J Med. 337:1997;1360-1369.
6. Buja L.M., Kita T., Goldstein J.L., Watanabe Y., Brown M.S. Cellular pathology of progressive atherosclerosis in the WHHL rabbit, an animal model of familial hypercholesterolemia. Arteriosclerosis. 3:1983;87-101.
7. Chandler A.B., Hand R.A. Phagocytized platelets. a source of lipids in human thrombi and atherosclerotic plaques Science. 134:1961;946-947.
8. Charpiot P., Rolland P.H., Friggi A. ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries. Arterioscler. Thromb. 13:1993;1125-1138.
9. Chobanian A., Handenschild C., Nickerson C., Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 15:1990;327-331.
10. Chopra M., Beswick H., Clapperton M., Dargie H.J., Smith W.E., McMurray J. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors. Free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors J Cardiovasc Pharmacol. 19:1992;330-340.
11. 1H-Nuclear magnetic resonance analysis Clin Chim Acta. 258:1997;193-200.
12. DeFelice E.A., Kostis J.B. New ACE inhibitors. Kostis J.B., DeFelice E.A. Angiotensin converting enzyme inhibitors. 1987;213-261 Alan R. Liss, New York.
13. DeForrest J.M., Waldron T.L., Krapcho J. Pre-clinical pharmacology of zofenopril, an inhibitor of angiotensin converting enzyme. J Cardiovasc Pharmacol. 13:1989;887-894.
14. Esterbauer H., Streigl G., Puhl H., Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun. 6:1989;67-75.
15. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 326:1992;310-318.
16. Fuster V. Mechanisms of arterial thrombosis. foundation for therapy Am Heart J. 135:1998;S361-S366.
17. Hale L.P., Craver K.T., Berrier A.M., Sheffield M.V., Case L.D., Owen J. Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys. Arterioscler Thromb Vasc Biol. 18:1998;1643-1646.
18. Hayek T., Attias J., Smith J., Breslow J.L., Keidar S. Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 31:1998;540-544.
19. Hernandez-Presa M.A., Bustos C., Ortego M., Tunon J., Ortega L., Egido J. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol. 153:1998;1825-1837.
20. Holmquist B., Bunning P., Riordan J. A spectrometric assay for angiotensin converting enzyme. Anal Biochem. 95:1979;540-544.
21. Itoh H., Cicala C., Douglas G.J., Page C.P. Platelet accumulation induced by bacterial endotoxin in rats. Thromb Res. 83:1996;405-419.
22. Keidar S., Oiknine J., Leiba A., Shapire C., Leiba M., Aviram M. Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients. J Cardiovasc Pharmacol. 27:1996;183-186.
23. Kinlay S., Selwyn A.P., Libby P., Ganz P. Inflammation, the endothelium, and the acute coronary syndromes. J Cardiovasc Pharmacol. 32:1998;S62-S66.
24. Kowala M.C., Valentine M., Recce R., Beyer S., Goller N., Durham S., Aberg G. Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and captopril. ACE in atheromas provides cellular targets for captopril J Cardiovasc Pharmacol. 32:1998;29-38.
25. Kruth H.S. Platelet-mediated cholesterol accumulation in cultured aortic smooth muscle cells. Science. 227:1985;1243-1245.
26. Lacourciere Y., Provencher P. Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. Br J Clin Pharmacol. 27:1989;371-376.
27. Linz W., Wiemer G., Gohlre P., Unger T., Scholkens B.A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme. Pharmacol Rev. 47:1995;25-49.
28. Liu J.T., Paul W., Ernesen M., Cicala C., Page C.P. Thrombin inhibitors and anticoagulants on thrombin-induced embolization in rabbit cranial vasculature. Eur J Pharmacol. 264:1994;183-190.
29. Loscalzo J. The relation between atherosclerosis and thrombosis. Circulation. 86:1992;III95-III99.
30. Lowry O.H., Rosebrough H.J., Farr A.L., Randall R.J. Protein measurement with the folin-phenol reagent. J Biol Chem. 193:1951;265-275.
31. Luscher T.F. Endothelial dysfunction in atherosclerosis. J Myocard Ischemia. 7:1995;15-20.
32. Mak I.T., Freedman A.M., Dickens B.F., Weglicki W.B. Protective effects of sulfhydryl-containing angiotensin-converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol. 40:1990;2169-2175.
33. Napoli C., Postiglione A., Triggiani M., Corso G., Palumbo G., Ambrosio G., Carbone V., Ruocco A., Montefusco S., Malorni A., Condorelli M., Chiariello M. Oxidative structural modifications of low density lipoprotein in homozygous familial hypercholesterolemia. Atherosclerosis. 118:1995;263-275.
34. Napoli C. Low density lipoprotein oxidation and variant angina. role of methodologic procedures in assessment of oxidizability of low density lipoprotein J Am Coll Cardiol. 28:1996;1637-1638.
35. Napoli C., Chiariello M., Palumbo G., Ambrosio G. Calcium channel blockers inhibit human low density lipoprotein oxidation by oxygen radicals. Cardiovasc Drugs Ther. 10:1996;417-424.
36. Napoli C., D'Armiento F.P., Mancini F.P., Witztum J.L., Palumbo G., Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 100:1997;2680-2690. a.
37. Napoli C., Mancini F.P., Corso G., Malorni A., Crescenzi E., Palumbo G. A simple and rapid purification procedure minimizes spontaneous oxidative modifications of low density lipoprotein and lipoprotein (a). J Biochemistry. 121:1997;1096-1101. b.
38. Napoli C., Ambrosio G., Scarpato N., Corso G., Palumbo G., D'Armiento F.P., Mancini F.P., Malorni A., Formisano S., Ruocco A., Calì A., Chiariello M. Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia. Am Heart J. 133:1997;585-595. c.
39. Napoli C., Paternò R., Faraci F.M., Taguchi H., Postiglione A., Heistad D.D. Mildly oxidized low-density lipoprotein impairs responses of carotid but not basilar artery in rabbits. Stroke. 28:1997;2266-2272. d.
40. Napoli C., Triggiani M., Palumbo G., Condorelli M., Chiariello M., Ambrosio G. Glycosylation enhances oxidation and decreases acetylhydrolase activity of human low density lipoprotein. Basic Res Cardiol. 92:1997;96-105. e.
41. Napoli C., Witztum J.L., de Nigris F., Palumbo G., D'Armiento F.P., Palinski W. Intracranial arteries of human fetuses are more resistant to hypercholesterolemia-induced fatty streak formation than extracranial arteries. Circulation. 99:1999;2003-2010. a.
42. Napoli C., Glass C.K., Witztum J.L., Deutch R., D'Armiento F.P., Palinski W. Progression of early atherosclerotic lesions in childhood is predetermined by maternal hypercholesterolemia during pregnancy. The Fate of Early Lesions in Children (FELIC) Study. Lancet. 354:1999;1234-1241. b.
43. Nichols T.C., Bellinger D.A., Tate D.A., Reddick R.L., Read M.S., Koch G.G., Brinkhous K.M., Griggs T.R. Von Willembrand factor and occlusive arterial thrombosis. a study in normal and von Willembrand's disease pigs with diet-induced hypercholesterolemia and atherosclerosis Arteriosclerosis. 10:1990;446-461.
44. Pitt B. The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia. Am J Cardiol. 79:1997;24-28.
45. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 340:1999;115-126.
46. Shiomi M., Ito T., Shiraishi M., Watanabe Y. Inheritability of atherosclerosis and the role of lipoproteins as risk factors related to coronary atherosclerosis in WHHL rabbits. Atherosclerosis. 96:1992;43-52.
47. Simic M.G. Mechanisms of inhibition of free-radical processes in mutagenesis and carcinogenesis. Mutat Res. 202:1988;377-386.
48. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 272:1997;20963-20966.
49. Sun Y., Mendelsohn F.A.O. Angiotensin converting enzyme inhibition in heart, kidney and serum studied ex vivo after administration of zofenopril, captopril and lisinopril. J Cardiovasc Pharmacol. 18:1991;478-486.
50. Tanzawa K., Shimada Y., Kuroda M., Tsujita Y., Arai M., Watanabe H. WHHL rabbit. a low density lipoprotein receptor-deficient animal model for familial hypercholesterolemia FEBS Letter. 118:1980;81-84.
51. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 88:1991;1785-1792.